Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
about
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung DiseaseDefining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart DiseaseRespiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infantsIncidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in ItalyRespiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).Cost, causes and rates of rehospitalization of preterm infants.Understanding the transmission dynamics of respiratory syncytial virus using multiple time series and nested models.Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis.Prematurity and the burden of influenza and respiratory syncytial virus disease.Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants.Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors?Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation.Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.
P2860
Q28067464-189B3393-0B6E-43F8-B692-66A8C3C5A695Q28072535-E9BA5F54-4C83-4474-B9EA-E1AADB01B45BQ30251560-B09522CE-03ED-4082-A3B7-A8C5D537578CQ31047460-407648A7-AA35-4BFC-A4E3-32F8CA09D4B8Q33501862-495CA448-73B8-462E-B60F-8A523EF83A09Q33630047-442AC37C-A80C-42D3-8DC5-165F4AA733D5Q36275397-5F3C7FB9-0267-4C46-86B6-B9AEF221DD58Q36918637-842F305B-27D9-4E03-ABC5-2037628D3CE5Q37046620-8AC3AD85-4C49-49DB-9A94-0675BFC0E3EEQ37290618-1802C2FF-0664-4529-B664-AEE7B0353ABEQ37975405-E83E2DDF-6C28-46F9-8F0A-4590F0B3DCAEQ38637989-76FCF5BF-B0A8-4CF0-B9A8-03078AD717E0Q41199983-4FF43A88-1B08-4EE4-92CB-39D97EDF8C74Q42204657-199960B8-905D-4343-8750-1158AEFA6D22Q43914636-040AF0CE-1401-4BEC-B388-6501A691617AQ45375474-BC47E839-1E29-4706-BE79-02EB8D45B04E
P2860
Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Hospital admission of high ris ...... s for palivizumab prophylaxis.
@en
Hospital admission of high ris ...... s for palivizumab prophylaxis.
@nl
type
label
Hospital admission of high ris ...... s for palivizumab prophylaxis.
@en
Hospital admission of high ris ...... s for palivizumab prophylaxis.
@nl
prefLabel
Hospital admission of high ris ...... s for palivizumab prophylaxis.
@en
Hospital admission of high ris ...... s for palivizumab prophylaxis.
@nl
P2093
P2860
P356
P1476
Hospital admission of high ris ...... s for palivizumab prophylaxis.
@en
P2093
Lehtonen L
Ruuskanen O
Vainionpää R
Valkonen H
P2860
P356
10.1136/ADC.2003.029710
P577
2005-01-01T00:00:00Z